Cipher Pharmaceuticals announces U.S. commercial entry through acquisition of INNOCUTIS

• Accelerates development of a leading North American dermatology company
• Adds U.S. commercial infrastructure for our acquisition/in-licensing activities
• Raises US$100 million Senior Notes to finance acquisition and future growth

MISSISSAUGA, ON, April 13, 2015 - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that it has acquired INNOCUTIS Holdings LLC ("INNOCUTIS"), a privately held specialty dermatology company, for US$45.5 million in cash. All financial references are in U.S. dollars unless otherwise noted.

Recro Pharma Completes Acquisition of IV/IM Meloxicam and cGMP Manufacturing Facility and Business Unit From Alkermes

- Transformative Acquisition Diversifies Recro Pharma's Development Risk with Second, Complementary Acute Pain Product
- Phase III-Ready, Long-Acting Injectable Meloxicam Has Demonstrated Robust Efficacy, Good Tolerability in Multiple Phase II Trials
- Transaction Includes Cash Flow Positive Manufacturing, Royalty and Formulation Business

MALVERN, Pa., April 13, 2015 -- Recro Pharma, Inc. (REPH) today announced the completion of its previously announced acquisition of assets from Alkermes plc and its affiliates including worldwide rights to IV/IM meloxicam, a proprietary, Phase III-ready, long-acting COX-2 NSAID for moderate to severe acute pain, and a contract manufacturing facility, royalty and formulation business.

Theralase Manufactures First Pre-Commercial Batch of Lead Anti-Cancer Drug

TORONTO, ON / April 9, 2015 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSX VENTURE:TLT) (PINKSHEETS:TLTFF(R)) announced today that it has successfully manufactured the first pre-commercial batch of its lead anti-cancer Photo Dynamic Compound ("PDC"), TLD-1433, one of a new generation of unique light-activated anti-cancer compounds, specifically developed for the treatment of cancer.

Drugs intended for in human clinical applications, such as TLD-1433, must be manufactured in accordance with Good Manufacturing Practices ("GMP") standards. To achieve GMP standards, the normal process is a "scale-up" in production from a small quantity to validate the manufacturing process to larger pre-commercial quantities demonstrating manufacturing optimization and finally commercial quantities, produced under strict GMP standards, suitable for human use.

BioBlast Pharma Announces Granting of Fast Track Designation by the FDA for Cabaletta in Oculopharyngeal Muscular Dystrophy (OPMD)

TEL AVIV, Israel, April 9, 2015 -  BioBlast Pharma Ltd. (ORPN), a clinical-stage, orphan disease-focused biotechnology company announced today that the United States Food and Drug Administration (FDA) has granted Fast Track designation to Cabaletta for the treatment of patients with Oculopharyngeal Muscular Dystrophy (OPMD).

Cabaletta is being developed to treat OPMD, a rare and debilitating muscular dystrophy for which there is no cure or approved therapy. BioBlast is currently conducting a Phase 2/3 clinical study for OPMD and recently announced the granting of an IND, enabling the opening of a US clinical center in addition to the two ongoing clinical sites in Israel and Canada.